While current guidelines in the use of insulin are effective in glycemic control and the reduction of UACR, GLP1-RA treatment could be a strong alternative in DKD due to their similar efficacy to insulin in reducing UACR with lower financial burdens and health risks. The gene discussed is INS; the disease is diabetic kidney disease.